[Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up].
Eighty-six patients with progressive systemic sclerosis were given coagulation factor XIII intravenously in different dosage regimens. The mean duration of treatment was 19 +/- 18 months and patients were followed up for 22.9 +/- 18.8 months. Improvement or stabilization of the lesions was obtained in 44/86 patients and exclusively concerned skin lesions; there was no improvement in visceral lesions. The drug was well tolerated in short-and long-term treatment. It is concluded that factor XIII demonstrated lasting effectiveness in one-half of the patients treated.
D000328:Adult; D000368:Aged; D005176:Factor XIII / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000503:physiopathology / Q000628:therapy*; D013997:Time Factors
D005176:Factor XIII
Traitement de la sclérodermie systémique par le facteur XIII chez 86 malades suivis à long terme.